|
1
|
Jo VY and Fletcher CD: WHO classification
of soft tissue tumours: An update based on the 2013 (4th) edition.
Pathology. 46:95–104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Taylor BS, Barretina J, Maki RG, Antonescu
CR, Singer S and Ladanyi M: Advances in sarcoma genomics and new
therapeutic targets. Nat Rev Cancer. 11:541–557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Linch M, Miah AB, Thway K, Judson IR and
Benson C: Systemic treatment of soft-tissue sarcoma-gold standard
and novel therapies. Nat Rev Clin Oncol. 11:187–202. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Whelan JS and Davis LE: Osteosarcoma,
chondrosarcoma, and chordoma. J Clin Oncol. 36:188–193. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takahashi M, Komine K, Imai H, Okada Y,
Saijo K, Takahashi M, Shirota H, Ohori H, Takahashi S, Chiba N, et
al: Efficacy and safety of gemcitabine plus docetaxel in Japanese
patients with unresectable or recurrent bone and soft tissue
sarcoma: Results from a single-institutional analysis. PLoS One.
12:e01769722017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kawai A, Araki N, Sugiura H, Ueda T,
Yonemoto T, Takahashi M, Morioka H, Hiraga H, Hiruma T, Kunisada T,
et al: Trabectedin monotherapy after standard chemotherapy versus
best supportive care in patients with advanced,
translocation-related sarcoma: A randomised, open-label, phase 2
study. Lancet Oncol. 16:406–416. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schoffski P, Chawla S, Maki RG, Italiano
A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, et
al: Eribulin versus dacarbazine in previously treated patients with
advanced liposarcoma or leiomyosarcoma: A randomised, open-label,
multicentre, phase 3 trial. Lancet. 387:1629–1637. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van der Graaf WT, Blay JY, Chawla SP, Kim
DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP,
Beppu Y, et al: Pazopanib for metastatic soft-tissue sarcoma
(PALETTE): A randomised, double-blind, placebo-controlled phase 3
trial. Lancet. 379:1879–1886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Uszczynska-Ratajczak B, Lagarde J,
Frankish A, Guigó R and Johnson R: Towards a complete map of the
human long non-coding RNA transcriptome. Nat Rev Genet. 19:535–548.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fang S, Zhang L, Guo J, Niu Y, Wu Y, Li H,
Zhao L, Li X, Teng X, Sun X, et al: NONCODEV5: A comprehensive
annotation database for long non-coding RNAs. Nucleic Acids Res.
46(D1): D308–D314. 2018. View Article : Google Scholar
|
|
11
|
Huarte M: The emerging role of lncRNAs in
cancer. Nat Med. 21:1253–1261. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sørensen KP, Thomassen M, Tan Q, Bak M,
Cold S, Burton M, Larsen MJ and Kruse TA: Long non-coding RNA
HOTAIR is an independent prognostic marker of metastasis in
estrogen receptor-positive primary breast cancer. Breast Cancer Res
Treat. 142:529–536. 2013. View Article : Google Scholar
|
|
13
|
Abdeahad H, Avan A, Pashirzad M, Khazaei
M, Soleimanpour S, Ferns GA, Fiuji H, Ryzhikov M, Bahrami A and
Hassanian SM: The prognostic potential of long noncoding RNA HOTAIR
expression in human digestive system carcinomas: A meta-analysis. J
Cell Physiol. 234:10926–10933. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ji P, Diederichs S, Wang W, Böing S,
Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et
al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict
metastasis and survival in early-stage non-small cell lung cancer.
Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun XH, Yang LB, Geng XL, Wang R and Zhang
ZC: Increased expression of lncRNA HULC indicates a poor prognosis
and promotes cell metastasis in osteosarcoma. Int J Clin Exp
Pathol. 8:2994–3000. 2015.PubMed/NCBI
|
|
16
|
Tian ZZ, Guo XJ, Zhao YM and Fang Y:
Decreased expression of long non-coding RNA MEG3 acts as a
potential predictor biomarker in progression and poor prognosis of
osteosarcoma. Int J Clin Exp Pathol. 8:15138–15142. 2015.PubMed/NCBI
|
|
17
|
Li Z, Dou P, Liu T and He S: Application
of long noncoding RNAs in osteosarcoma: Biomarkers and therapeutic
targets. Cell Physiol Biochem. 42:1407–1419. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matsuzaki J and Ochiya T: Circulating
microRNAs and extracellular vesicles as potential cancer
biomarkers: A systematic review. Int J Clin Oncol. 22:413–420.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hakozaki M, Hojo H, Sato M, Tajino T,
Yamada H, Kikuchi S and Abe M: Establishment and characterization
of a novel human malignant peripheral nerve sheath tumor cell line,
FMS-1, that overexpresses epidermal growth factor receptor and
cyclooxygenase-2. Virchows Arch. 455:517–526. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aoki M, Nabeshima K, Nishio J, Ishiguro M,
Fujita C, Koga K, Hamasaki M, Kaneko Y and Iwasaki H: Establishment
of three malignant peripheral nerve sheath tumor cell lines,
FU-SFT8611, 8710 and 9817: Conventional and molecular cytogenetic
characterization. Int J Oncol. 29:1421–1428. 2006.PubMed/NCBI
|
|
21
|
Frahm S, Mautner VF, Brems H, Legius E,
Debiec-Rychter M, Friedrich RE, Knöfel WT, Peiper M and Kluwe L:
Genetic and phenotypic characterization of tumor cells derived from
malignant peripheral nerve sheath tumors of neurofibromatosis type
1 patients. Neurobiol Dis. 16:85–91. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Masuzawa M, Fujimura T, Hamada Y, Fujita
Y, Hara H, Nishiyama S, Katsuoka K, Tamauchi H and Sakurai Y:
Establishment of a human hemangiosarcoma cell line (ISO-HAS). Int J
Cancer. 81:305–308. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kumar R, Knick VB, Rudolph SK, Johnson JH,
Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE,
Onori JA, et al: Pharmacokinetic-pharmacodynamic correlation from
mouse to human with pazopanib, a multikinase angiogenesis inhibitor
with potent antitumor and antiangiogenic activity. Mol Cancer Ther.
6:2012–2021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hurwitz HI, Dowlati A, Saini S, Savage S,
Suttle AB, Gibson DM, Hodge JP, Merkle EM and Pandite L: Phase I
trial of pazopanib in patients with advanced cancer. Clin Cancer
Res. 15:4220–4227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li ZX, Zhu QN, Zhang HB, Hu Y, Wang G and
Zhu YS: MALAT1: A potential biomarker in cancer. Cancer Manag Res.
10:6757–6768. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qu X, Alsager S, Zhuo Y and Shan B: HOX
transcript antisense RNA (HOTAIR) in cancer. Cancer Lett.
454:90–97. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marín-Béjar O, Marchese FP, Athie A,
Sánchez Y, González J, Segura V, Huang L, Moreno I, Navarro A,
Monzó M, et al: Pint lincRNA connects the p53 pathway with
epigenetic silencing by the Polycomb repressive complex 2. Genome
Biol. 14:R1042013. View Article : Google Scholar
|
|
30
|
Sánchez Y, Segura V, Marín-Béjar O, Athie
A, Marchese FP, González J, Bujanda L, Guo S, Matheu A and Huarte
M: Genome-wide analysis of the human p53 transcriptional network
unveils a lncRNA tumour suppressor signature. Nat Commun.
5:58122014. View Article : Google Scholar
|
|
31
|
Campos-Parra AD, López-Urrutia E, Orozco
Moreno LT, López-Camarillo C, Meza-Menchaca T, Figueroa González G,
Bustamante Montes LP and Pérez-Plasencia C: Long non-coding RNAs as
new master regulators of resistance to systemic treatments in
breast cancer. Int J Mol Sci. 19:27112018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pollard KS, Salama SR, Lambert N, Lambot
MA, Coppens S, Pedersen JS, Katzman S, King B, Onodera C, Siepel A,
et al: An RNA gene expressed during cortical development evolved
rapidly in humans. Nature. 443:167–172. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu H, Li J, Koirala P, Ding X, Chen B,
Wang Y, Wang Z, Wang C, Zhang X and Mo YY: Long non-coding RNAs as
prognostic markers in human breast cancer. Oncotarget.
7:20584–20596. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma B, Liao T, Wen D, Dong C, Zhou L, Yang
S, Wang Y and Ji Q: Long intergenic non-coding RNA 271 is
predictive of a poorer prognosis of papillary thyroid cancer. Sci
Rep. 6:369732016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shi Z, Luo Y, Zhu M, Zhou Y, Zheng B, Wu
D, Wang S, Xie X, Lin H and Yu X: Expression analysis of long
non-coding RNA HAR1A and HAR1B in HBV-induced hepatocullular
carcinoma in Chinese patients. Lab Med. 50:150–157. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Starke RD, Ferraro F, Paschalaki KE,
Dryden NH, McKinnon TA, Sutton RE, Payne EM, Haskard DO, Hughes AD,
Cutler DF, et al: Endothelial von Willebrand factor regulates
angiogenesis. Blood. 117:1071–1080. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nilsson HE, Ambort D, Backstrom M,
Thomsson E, Koeck PJ, Hansson GC and Hebert H: Intestinal MUC2
mucin supramolecular topology by packing and release resting on D3
domain assembly. J Mol Biol. 426:2567–2579. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nakamura Y, Hasebe A, Takahashi K, Iijima
M, Yoshimoto N, Maturana AD, Ting K, Kuroda S and Niimi T:
Oligomerization-induced conformational change in the C-terminal
region of Nel-like molecule 1 (NELL1) protein is necessary for the
efficient mediation of murine MC3T3-E1 cell adhesion and spreading.
J Biol Chem. 289:9781–9794. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu ER, Blythe EE, Fischer G and Hyvönen M:
Structural analyses of von Willebrand factor C domains of collagen
2A and CCN3 reveal an alternative mode of binding to bone
morphogenetic protein-2. J Biol Chem. 292:12516–12527. 2017.
View Article : Google Scholar : PubMed/NCBI
|
